DATROWAY AstraZeneca Pty Ltd
Product name
DATROWAY
Sponsor
Accepted date
May-2024
Active ingredients
datopotamab deruxtecan
Proposed indication
For the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease.
Application type
A (new medicine)
Publication date
May-2024